STTR Phase II: VaxMAP a single dose multivalent vaccine to produce durable and cross-reactive immunity against various coronaviruses
STTR II 期:VaxMAP 一种单剂量多价疫苗,可产生针对各种冠状病毒的持久和交叉反应免疫力
基本信息
- 批准号:2308751
- 负责人:
- 金额:$ 100万
- 依托单位:
- 依托单位国家:美国
- 项目类别:Cooperative Agreement
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-15 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project will address the unmet need for more effective vaccines that can be rapidly deployed to decrease the lag time between pathogen emergence and vaccine development, minimizing socioeconomic effects such as those seen in the COVID-19 pandemic. This new vaccine technology has the potential to drastically improve the lives of US citizens during future outbreaks of new pathogens. Further, this new technology has the potential to have positive impacts by providing high value US products for the whole world and generating US jobs both in research fields and manufacturing of biotechnology products. Successful completion of this STTR phase II project will position the company with a technology that has potential multiple partnership opportunities including biotechnology and pharmaceutical businesses developing antigens for vaccines against SARS-CoV-2. By developing this new vaccine platform technology, the company will be able to gain access to a significant segment of the global vaccine market estimated at $61 billion in 2021 and projected to grow to $125 billion by 2028. This Small Business Technology Transfer (STTR) Phase II project will enable the company to pursue the development of a new vaccine platform with robust and long-lasting vaccination responses against emergent pathogens. Although effective COVID-19 vaccines are now available to fight the global pandemic that started in 2019, they are facing significant limitations including diminished efficacy against new spreading variants, requirements for multiple doses, and challenging distribution pathways due to cold chain issues. The research objectives are to determine the optimal dose of the vaccine in a murine immunization model, understand the durability of its immune response, assess the vaccine's protective immunity against different SARS-CoV-2 variants, evaluate the vaccine shelf-life stability and develop a regulatory plan. Based on the successful preliminary data, it is anticipated that the new product will generate protective immunity against multiple variants of SARS-CoV-2 by providing a long-lasting immune response that will result in longer-lasting protection against infection when compared to current vaccines. Furthermore, the shelf-life and storage conditions of the new vaccine platform are anticipated to facilitate distribution and stockpiling, as no drastic cold chain logistics are expected.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
小企业技术转让(STTR)第二阶段项目的更广泛影响/商业潜力将解决对更有效疫苗的未满足需求,这些疫苗可以快速部署,以减少病原体出现和疫苗开发之间的滞后时间,最大限度地减少社会经济影响,如COVID-19大流行中所见的影响。这项新的疫苗技术有可能在未来新病原体爆发期间大大改善美国公民的生活。此外,这项新技术有可能产生积极的影响,为全世界提供高价值的美国产品,并在研究领域和生物技术产品的制造方面为美国创造就业机会。STTR第二阶段项目的成功完成将使该公司拥有一项具有潜在的多重合作机会的技术,包括开发SARS-CoV-2疫苗抗原的生物技术和制药企业。通过开发这种新的疫苗平台技术,该公司将能够进入全球疫苗市场的重要部分,预计到2021年将达到610亿美元,预计到2028年将增长到1250亿美元。这个小企业技术转让(STTR)第二阶段项目将使该公司能够开发一个新的疫苗平台,对新出现的病原体具有强大和持久的疫苗接种反应。尽管有效的COVID-19疫苗现已可用于对抗始于2019年的全球大流行,但它们面临着重大限制,包括对新传播变种的效力降低,需要多次接种,以及由于冷链问题而具有挑战性的分销途径。研究目的是确定疫苗在小鼠免疫模型中的最佳剂量,了解其免疫应答的持久性,评估疫苗对不同SARS-CoV-2变体的保护性免疫力,评估疫苗的保质期稳定性并制定监管计划。根据成功的初步数据,预计新产品将通过提供持久的免疫应答产生针对SARS-CoV-2多种变体的保护性免疫,与目前的疫苗相比,这种免疫应答将导致更持久的感染保护。此外,新疫苗平台的保质期和储存条件预计将有助于分销和储存,因为预计不会出现激烈的冷链物流。该奖项反映了NSF的法定使命,并通过使用基金会的知识价值和更广泛的影响审查标准进行评估,被认为值得支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephanie Deshayes其他文献
Stephanie Deshayes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephanie Deshayes', 18)}}的其他基金
SBIR Phase I: A new vaccine technology to engineer a potent and polarized immunity against COVID-19
SBIR 第一阶段:一种新的疫苗技术,可针对 COVID-19 产生强大的极化免疫力
- 批准号:
2031727 - 财政年份:2020
- 资助金额:
$ 100万 - 项目类别:
Standard Grant
相似国自然基金
Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark
Supercooled Phase Transition
- 批准号:24ZR1429700
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
ATLAS实验探测器Phase 2升级
- 批准号:11961141014
- 批准年份:2019
- 资助金额:3350 万元
- 项目类别:国际(地区)合作与交流项目
地幔含水相Phase E的温度压力稳定区域与晶体结构研究
- 批准号:41802035
- 批准年份:2018
- 资助金额:12.0 万元
- 项目类别:青年科学基金项目
基于数字增强干涉的Phase-OTDR高灵敏度定量测量技术研究
- 批准号:61675216
- 批准年份:2016
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Phase-type分布的多状态系统可靠性模型研究
- 批准号:71501183
- 批准年份:2015
- 资助金额:17.4 万元
- 项目类别:青年科学基金项目
纳米(I-Phase+α-Mg)准共晶的临界半固态形成条件及生长机制
- 批准号:51201142
- 批准年份:2012
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
连续Phase-Type分布数据拟合方法及其应用研究
- 批准号:11101428
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
D-Phase准晶体的电子行为各向异性的研究
- 批准号:19374069
- 批准年份:1993
- 资助金额:6.4 万元
- 项目类别:面上项目
相似海外基金
STTR Phase II: Fabrication and Structural Testing of a 3D Concrete Printed Anchor for Floating Offshore Wind
STTR 第二阶段:用于浮动海上风电的 3D 混凝土打印锚的制造和结构测试
- 批准号:
2333306 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Optimized manufacturing and machine learning based automation of Endothelium-on-a-chip microfluidic devices for drug screening applications.
STTR 第二阶段:用于药物筛选应用的片上内皮微流体装置的优化制造和基于机器学习的自动化。
- 批准号:
2332121 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Earth-abundant catalyst for power-to-liquids chemical production at the kiloton scale
STTR 第二阶段:地球储量丰富的催化剂,用于千吨级电力转化为液体的化学生产
- 批准号:
2304275 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Dermatologist-level detection of suspicious pigmented skin lesions from high-resolution full-body images
STTR II 期:通过高分辨率全身图像对可疑色素性皮肤病变进行皮肤科医生级别的检测
- 批准号:
2335086 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Thermal Imaging, Augmentation of Microwave Energy in Various Tissues and Chronic Safety
STTR 第二阶段:热成像、增强各种组织中的微波能量和长期安全性
- 批准号:
2301440 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Nanomaterial-based Residual Active Disinfectant for Decreasing Surface Acquired Infections
STTR 第二阶段:基于纳米材料的残留活性消毒剂,用于减少表面获得性感染
- 批准号:
2208717 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Scaling the Purification of Mycosporine-like Amino Acids to Replace Chemical Ultraviolet (UV) Filters and Protect Human and Environmental Health.
STTR 第二阶段:扩大类菌孢素氨基酸的纯化,以取代化学紫外线 (UV) 过滤器并保护人类和环境健康。
- 批准号:
2222582 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Stem Cell Delivery in Microscopic Hydrogel Droplets for Faster and More Complete Healing of Equine Tendon and Ligament Injuries
STTR 第二阶段:以微小水凝胶液滴形式输送干细胞,以更快、更完全地治愈马肌腱和韧带损伤
- 批准号:
2304324 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Development of a Smart Remote Health Management System for Patients with Kidney Disease
STTR二期:为肾病患者开发智能远程健康管理系统
- 批准号:
2243718 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
STTR Phase II: Body fluid identification for forensic purposes using Raman spectroscopy
STTR 第二阶段:使用拉曼光谱法进行体液鉴定
- 批准号:
2304318 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement